Branded Generics Market Size, Share & Trends Report

Branded Generics Market Size, Share & Trends Analysis By Drug Class (Alkylating Agents, Antimetabolites, Anti-Hypertensive), By Application, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

Report ID: GVR-4-68039-943-5
Number of Pages: 155
Format: Electronic (PDF)

Historical Range: 2018 - 2021
Industry: Healthcare

Market Segmentation

Branded Generics Market Drug Class Outlook, (Revenue, USD Billion, 2018 - 2030)
- Alkylating Agents
- Antimetabolites
- Hormones
- Anti-Hypertensive
- Lipid Lowering Drugs
- Anti-Depressants
- Anti-Psychotics
- Anti-Epileptics
- Others
Branded Generics Market Application Outlook, (Revenue, USD Billion, 2018 - 2030)
- Oncology
- Cardiovascular Diseases
- Neurological Diseases
- Gastrointestinal Diseases
- Dermatological Diseases
- Acute and Chronic Pain
- Others
Branded Generics Market Route of Administration Outlook, (Revenue, USD Billion, 2018 - 2030)
- Topical
- Oral
- Parenteral
- Others
Branded Generics Market Distribution Channel Outlook, (Revenue, USD Billion, 2018 - 2030)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Branded Generics Market Regional Outlook (Revenue, USD Billion, 2018- 2030)
- North America
  - North America Drug Class Outlook, Revenue, USD Billion, 2018- 2030
    - Alkylating Agents
    - Antimetabolites
    - Hormones
    - Anti-Hypertensive
    - Lipid Lowering Drugs
    - Anti-Depressants
    - Anti-Psychotics
    - Anti-Epileptics
    - Others
  - North America Application Outlook, Revenue, USD Billion, 2018- 2030
    - Oncology
    - Cardiovascular Diseases
    - Neurological Diseases
    - Gastrointestinal Diseases
    - Dermatological Diseases
    - Acute and Chronic Pain
    - Others
  - North America Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
    - Topical
    - Oral
    - Parenteral
    - Others
  - North America Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
    - Hospital Pharmacy
    - Retail Pharmacy
    - Online Pharmacy
  - U.S.
    - U.S. Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - U.S. Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - U.S. Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - U.S. Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
  - Canada
    - Canada Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - Canada Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - Canada Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - Canada Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
- Europe
  - Europe Drug Class Outlook, Revenue, USD Billion, 2018- 2030
    - Alkylating Agents
    - Antimetabolites
    - Hormones
    - Anti-Hypertensive
    - Lipid Lowering Drugs
    - Anti-Depressants
    - Anti-Psychotics
    - Anti-Epileptics
    - Others
  - Europe Application Outlook, Revenue, USD Billion, 2018- 2030
    - Oncology
    - Cardiovascular Diseases
    - Neurological Diseases
    - Gastrointestinal Diseases
    - Dermatological Diseases
    - Acute and Chronic Pain
    - Others
  - Europe Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
    - Topical
    - Oral
    - Parenteral
    - Others
  - Europe Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
    - Hospital Pharmacy
    - Retail Pharmacy
    - Online Pharmacy
  - Germany
    - Germany Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - Germany Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - Germany Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - Germany Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
  - UK
    - UK Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - UK Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - UK Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - UK Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
  - France
    - France Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - France Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - France Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - France Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
  - Italy
    - Italy Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - Italy Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - Italy Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - Italy Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
  - Spain
    - Spain Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - Spain Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - Spain Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - Spain Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
  - Denmark
    - Denmark Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - Denmark Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - Denmark Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - Denmark Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
  - Sweden
    - Sweden Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - Sweden Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - Sweden Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - Sweden Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
  - Norway
    - Norway Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - Norway Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - Norway Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - Norway Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
- Asia Pacific
  - Asia Pacific Drug Class Outlook, Revenue, USD Billion, 2018- 2030
    - Alkylating Agents
    - Antimetabolites
    - Hormones
    - Anti-Hypertensive
    - Lipid Lowering Drugs
    - Anti-Depressants
    - Anti-Psychotics
    - Anti-Epileptics
    - Others
  - Asia Pacific Application Outlook, Revenue, USD Billion, 2018- 2030
    - Oncology
    - Cardiovascular Diseases
    - Neurological Diseases
    - Gastrointestinal Diseases
    - Dermatological Diseases
    - Acute and Chronic Pain
    - Others
  - Asia Pacific Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
    - Topical
    - Oral
    - Parenteral
    - Others
  - Asia Pacific Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
    - Hospital Pharmacy
    - Retail Pharmacy
    - Online Pharmacy
  - Japan
    - Japan Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - Japan Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - Japan Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - Japan Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
  - China
    - China Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - China Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - China Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - China Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
  - India
    - India Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - India Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - India Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - India Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
  - Australia
    - Australia Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - Australia Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - Australia Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - Australia Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
  - South Korea
    - South Korea Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - South Korea Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - South Korea Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - South Korea Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
  - Thailand
    - Thailand Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - Thailand Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - Thailand Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - Thailand Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
- Latin America
  - Latin America Drug Class Outlook, Revenue, USD Billion, 2018- 2030
    - Alkylating Agents
    - Antimetabolites
    - Hormones
    - Anti-Hypertensive
    - Lipid Lowering Drugs
    - Anti-Depressants
    - Anti-Psychotics
    - Anti-Epileptics
    - Others
  - Latin America Application Outlook, Revenue, USD Billion, 2018- 2030
    - Oncology
    - Cardiovascular Diseases
    - Neurological Diseases
    - Gastrointestinal Diseases
    - Dermatological Diseases
    - Acute and Chronic Pain
    - Others
  - Latin America Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
    - Topical
    - Oral
    - Parenteral
    - Others
  - Latin America Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
    - Hospital Pharmacy
    - Retail Pharmacy
    - Online Pharmacy
  - Brazil
    - Brazil Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - Brazil Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - Brazil Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - Brazil Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
  - Mexico
    - Mexico Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - Mexico Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - Mexico Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - Mexico Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
  - Argentina
    - Argentina Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - Argentina Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - Argentina Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - Argentina Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
- Middle East And Africa (MEA)
  - MEA Drug Class Outlook, Revenue, USD Billion, 2018- 2030
    - Alkylating Agents
    - Antimetabolites
    - Hormones
    - Anti-Hypertensive
    - Lipid Lowering Drugs
    - Anti-Depressants
    - Anti-Psychotics
    - Anti-Epileptics
    - Others
  - MEA Application Outlook, Revenue, USD Billion, 2018- 2030
    - Oncology
    - Cardiovascular Diseases
    - Neurological Diseases
    - Gastrointestinal Diseases
    - Dermatological Diseases
    - Acute and Chronic Pain
    - Others
  - MEA Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
    - Topical
    - Oral
    - Parenteral
    - Others
  - MEA Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
    - Hospital Pharmacy
    - Retail Pharmacy
    - Online Pharmacy
  - South Africa
    - South Africa Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - South Africa Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - South Africa Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - South Africa Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
  - Saudi Arabia
    - Saudi Arabia Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - Saudi Arabia Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - Saudi Arabia Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - Saudi Arabia Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
  - UAE
    - UAE Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - UAE Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - UAE Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - UAE Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
  - Kuwait
    - Kuwait Drug Class Outlook, Revenue, USD Billion, 2018- 2030
      - Alkylating Agents
      - Antimetabolites
      - Hormones
      - Anti-Hypertensive
      - Lipid Lowering Drugs
      - Anti-Depressants
      - Anti-Psychotics
      - Anti-Epileptics
      - Others
    - Kuwait Application Outlook, Revenue, USD Billion, 2018- 2030
      - Oncology
      - Cardiovascular Diseases
      - Neurological Diseases
      - Gastrointestinal Diseases
      - Dermatological Diseases
      - Acute and Chronic Pain
      - Others
    - Kuwait Route of Administration Outlook, Revenue, USD Billion, 2018- 2030
      - Topical
      - Oral
      - Parenteral
      - Others
    - Kuwait Distribution Channel Outlook, Revenue, USD Billion, 2018- 2030
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy

Branded Generics Market Dynamics

Driver: Patent expiry of branded products

Branded drugs, such as Revlimid and Alimta, may cost up to USD 500 a month, which affects the overall healthcare expenditure and affordability of patients suffering from chronic diseases. The expiry of patent exclusivity of innovator drugs provides opportunities for generic manufacturers to introduce products in the market at a reduced price. The low cost of generic drugs increases their affordability for patients and helps in the reduction of healthcare expenditure per capita. The expiry of product patents creates opportunities for generic and biosimilar manufacturers. Moreover, companies have filed ANDA for generics whose originator product patent expired. For instance, as the U.S. patent exclusivity period of Bristol-Myers Squibb Company proprietary Sprycel (Dasatinib) has come to an end, generic companies such as Apotex and Dr. Reddy’s Laboratories have filed ANDA for the launch of generic versions of the product. Following the expiration of the Indian patent in April 2020, generic versions of dasatinib are available for the treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL), resulting in significant cost savings.

Restraint: Pricing pressures

Governments are focusing on reducing healthcare expenditure by changing pricing policies. According to the Association for Accessible Medicines report, around 20% of the generic products accounted for the total expenditure on pharmaceuticals by value. The pricing of generic products is affected by significant consolidation and various commercial alliances between large buying groups. In January 2018, Amazon, Berkshire Hathaway, and JP Morgan Chase & Co. announced the formation of an independent healthcare company for their combined one million U.S. employees. This initiative is anticipated to increase competition and price erosion. These changes in the traditional supply chain may leverage increased negotiation for customers and additional pricing pressure. Moreover, individual manufacturers have minimal control over market pricing because several manufacturers are competing. This is exacerbated further by the fact that payment for generic products is capped and not directly linked to the cost of procurement for specific medications.

Opportunity: Government initiatives promoting generics usage

Originator products are very costly and thus affect out-of-pocket expenses of patients and overall healthcare expenses of governments. To contain excessive expenditure on pharmaceuticals, governments are introducing various strategies and initiatives to promote generic products. To reduce pharmaceutical spending, governments have undertaken initiatives that provide various opportunities to key generic players. For instance, the U.S. government saved USD 338.4 billion on generic drugs in 2020. Moreover, 90% of the prescriptions are filled by generic products, which account for 20% of the prescription drug expenses, according to AAM Generic Drug & Biosimilars Access & Savings Report 2021.

What Does This Report Include?

This section will provide insights into the contents included in this branded generics market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Branded generics market qualitative analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Branded generics market quantitative analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.